SCOPUS 정보 검색 플랫폼

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 2, 2013, Pages 273-277

Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692)

(2) Christopher, John A a Congreve, Miles S a

a Heptares Therapeutics Ltd (United Kingdom)

Author keywords

DORA; Insomnia; Orexin; OX1 antagonist; OX2 antagonist; Sleep disorders; Taisho Pharmaceutical Co. Ltd.

Indexed keywords

MK 6096; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PYRAZOLE DERIVATIVE; RECEPTOR BLOCKING AGENT; SUVOREXANT; UNCLASSIFIED DRUG; WO 2012081692;

ARTICLE; DEPROTECTION REACTION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; SLEEP DISORDER; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION;

ANIMALS; DRUG DESIGN; HUMANS; HYPNOTICS AND SEDATIVES; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PYRAZOLES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP; SLEEP DISORDERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872697616 PISSN: 13543776 EISSN: 17447674 Source Type: Journal
DOI: 10.1517/13543776.2013.749240 Document Type: Article

Times cited : (1)

References (19)

1
- 20244380014
- Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior
- DOI 10.1016/S0092-8674(00)80949-6
- Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85 (Pubitemid 28101119)
- (1998) Cell , vol.92 , Issue.4 , pp. 573-585
- Sakurai, T.¹ Amemiya, A.² Ishii, M.³ Matsuzaki, I.⁴ Chemelli, R.M.⁵ Tanaka, H.⁶ Williams, S.C.⁷ Richardson, J.A.⁸ Kozlowski, G.P.⁹ Wilson, S.¹⁰ Arch, J.R.S.¹¹ Buckingham, R.E.¹² Haynes, A.C.¹³ Carr, S.A.¹⁴ Annan, R.S.¹⁵ McNulty, D.E.¹⁶ Liu, W.-S.¹⁷ Terrett, J.A.¹⁸ Elshourbagy, N.A.¹⁹ Bergsma, D.J.²⁰ Yanagisawa, M.²¹ more..

2
- 64349107463
- Biomedical application of orexin/hypocretin receptor ligands in neuroscience
- Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52(4):891-903
- (2009) J Med Chem , vol.52 , Issue.4 , pp. 891-903
- Boss, C.¹ Brisbare-Roch, C.² Jenck, F.³

3
- 0033588184
- Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
- DOI 10.1016/S0092-8674(00)81973-X
- Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-51 (Pubitemid 29402482)
- (1999) Cell , vol.98 , Issue.4 , pp. 437-451
- Chemelli, R.M.¹ Willie, J.T.² Sinton, C.M.³ Elmquist, J.K.⁴ Scammell, T.⁵ Lee, C.⁶ Richardson, J.A.⁷ Clay Williams, S.⁸ Xiong, Y.⁹ Kisanuki, Y.¹⁰ Fitch, T.E.¹¹ Nakazato, M.¹² Hammer, R.E.¹³ Saper, C.B.¹⁴ Yanagisawa, M.¹⁵

4
- 2342602218
- Expression of a Poly-Glutamine-Ataxin-3 Transgene in Orexin Neurons Induces Narcolepsy-Cataplexy in the Rat
- DOI 10.1523/JNEUROSCI.5560-03.2004
- Beuckmann CT, Sinton CM, Williams SC, et al. Expression of a polyglutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 2004;24(18): 4469-77 (Pubitemid 38608158)
- (2004) Journal of Neuroscience , vol.24 , Issue.18 , pp. 4469-4477
- Beuckmann, C.T.¹ Sinton, C.M.² Williams, S.C.³ Richardson, J.A.⁴ Hammer, R.E.⁵ Sakurai, T.⁶ Yanagisawa, M.⁷

5
- 0033529520
- The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
- DOI 10.1016/S0092-8674(00)81965-0
- Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) receptor 2 gene. Cell 1999;98(3):365-76 (Pubitemid 29380571)
- (1999) Cell , vol.98 , Issue.3 , pp. 365-376
- Lin, L.¹ Faraco, J.² Li, R.³ Kadotani, H.⁴ Rogers, W.⁵ Lin, X.⁶ Qiu, X.⁷ De Jong, P.J.⁸ Nishino, S.⁹ Mignot, E.¹⁰

6
- 48249109864
- Orexin receptor antagonists: Medicinal chemistry and therapeutic potential
- Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8(11):977-87
- (2008) Curr Top Med Chem , vol.8 , Issue.11 , pp. 977-987
- Roecker, A.J.¹ Coleman, P.J.²

7
- 77649157819
- Orexin receptor antagonists: A review of promising compounds patented since 2006
- Coleman PJ, Renger JJ. Orexin receptor antagonists: A review of promising compounds patented since 2006. Expert Opin Ther Patents 2010;20(3):307-24
- (2010) Expert Opin Ther Patents , vol.20 , Issue.3 , pp. 307-324
- Coleman, P.J.¹ Renger, J.J.²

8
- 84872721871
- Orexin receptor antagonists
- Christopher JA. Orexin receptor antagonists. Pharm Pat Analyst 2012;1(3):329-46
- (2012) Pharm Pat Analyst , vol.1 , Issue.3 , pp. 329-346
- Christopher, J.A.¹

9
- 77649157819
- Orexin receptor antagonists: A review of promising compounds patented since 2006
- Coleman PJ, Renger JJ. Orexin receptor antagonists: A review of promising compounds patented since 2006. Expert Opin Ther Patents 2010;20(3):307-24
- (2010) Expert Opin Ther Patents , vol.20 , Issue.3 , pp. 307-324
- Coleman, P.J.¹ Renger, J.J.²

10
- 77955114579
- Orexin receptor antagonists: A new concept in CNS disorders?
- Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: A new concept in CNS disorders? ChemMedChem 2010;5(8):1197-214
- (2010) ChemMedChem , vol.5 , Issue.8 , pp. 1197-1214
- Gatfield, J.¹ Brisbare-Roch, C.² Jenck, F.³ Boss, C.⁴

11
- 58149394620
- Orexin receptor antagonism: A new principle in neuroscience
- Boss C, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonism: A new principle in neuroscience. Chimia (Aarau) 2008;62(12):974-9
- (2008) Chimia (Aarau) , vol.62 , Issue.12 , pp. 974-979
- Boss, C.¹ Brisbare-Roch, C.² Jenck, F.³

12
- 77954731181
- Discovery of the dual orexin receptor antagonist [(7R)-4-(5-Chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl) phenyl]methanone (MK-4305) for the treatment of insomnia
- Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53(14):5320-32
- (2010) J Med Chem , vol.53 , Issue.14 , pp. 5320-5332
- Cox, C.D.¹ Breslin, M.J.² Whitman, D.B.³

13
- 79956003278
- Promotion of sleep by suvorexant - A novel dual orexin receptor antagonist
- Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant - a novel dual orexin receptor antagonist. J Neurogenet 2011;25(1-2):52-61
- (2011) J Neurogenet , vol.25 , Issue.1-2 , pp. 52-61
- Winrow, C.J.¹ Gotter, A.L.² Cox, C.D.³

14
- 84872734008
- Available From. [Last accessed 14 September 2012]
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK4305 in Patients With Primary Insomnia - Study B. Available from: www.clinicaltrials.gov/ct2/ results?term=NCT01097629 [Last accessed 14 September 2012]
- Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Study To Evaluate The Safety and Efficacy of MK4305 in Patients With Primary Insomnia - Study B
- A Phase, I.I.I.¹

15
- 84872727777
- Available From. [Last accessed 14 September 2012]
- Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia. Available from: www.merck. com/newsroom/news-release-archive/research-and- development/2012-0206. html [Last accessed 14 September 2012]
- Merck Provides Update On Development Program For Suvorexant An Investigational Orexin Receptor Antagonist For The Treatment of Insomnia

16
- 84855982509
- Pharmacological characterization of mk-6096 - A dual orexin receptor antagonist for insomnia
- Winrow CJ, Gotter AL, Cox CD, et al. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 2011;62(2):978-87
- (2011) Neuropharmacology , vol.62 , Issue.2 , pp. 978-987
- Winrow, C.J.¹ Gotter, A.L.² Cox, C.D.³

17
- 84872723635
- Available From. [Last accessed 14 September 2012]
- Polysomnography Study of MK6096 in Patients With Primary Insomnia. Available from: www.clinicaltrials.gov/ct2/resultsterm=NCT01021852 [Last accessed 14 September 2012]
- Polysomnography Study of MK6096 in Patients With Primary Insomnia

18
- 84995620653
- Merck & Co. Inc. WO011775
- Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists. WO011775; 2009
- (2009) Amidoethyl Alkylamino Orexin Receptor Antagonists

19
- 84872718866
- Actelion Pharmaceuticals Ltd. WO022311
- Actelion Pharmaceuticals Ltd. 1,2-Diamido-ethylene derivatives. WO022311; 2009.
- (2009) 1,2-Diamido-ethylene derivatives

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.